Artiva shareholders approve 5.1M share increase to 2024 equity plan at annual meeting

Artiva Biotherapeutics, Inc.

Stockholders approved amendment to 2024 Equity Incentive Plan adding 5,097,095 shares to Share Reserve.
Vote on plan amendment: 32,527,133 for, 6,816,989 against, 22,759 abstentions, 4,640,922 broker non-votes.
Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. elected for three-year terms through 2029.
KPMG LLP ratified as independent auditor for FY2026: 44,000,762 for, 4,325 against, 2,716 abstentions.
Amended plan also counts pre-funded warrant shares in annual automatic reserve increase (starting Jan 1, 2027).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.